Navigation Links
Cancer Research Institute Celebrating 60th Anniversary, Honoring Immunotherapy Leaders

NEW YORK, Aug. 21, 2013 /PRNewswire/ -- The Cancer Research Institute (CRI), a New York-based nonprofit committed to developing immune system-based cancer treatments, is presenting serial tech entrepreneur and philanthropist Sean Parker and MedImmune biotech head Dr. Bahija Jallal with its highest honor for people exceptionally dedicated to advancing cancer research. They will receive the award at CRI's 27th annual awards dinner on Sep. 30 at Cipriani 42nd Street.

Cancer Research Institute is also celebrating its 60th year dedicated to funding and finding immunotherapy treatments for cancer with an "Immunotherapy Rocks Cancer" theme. Cancer immunotherapy is a new class of cancer treatment that mobilizes the immune system to fight the disease and represents the most immediate hope for curing patients with any type of cancer.

"We are so pleased to reach this huge milestone for Cancer Research Institute at such an exciting time in the field of cancer immunology," said Jill O'Donnell Tormey, Ph.D., CEO and director of scientific affairs at CRI. "The research and treatments happening right now are really fulfilling the promise that we've seen in cancer immunology for decades. That's why we honor the people who are so dedicated to advancing this field and making it a reality."

This year CRI will give the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research to Sean Parker for his work with Stand Up to Cancer and outstanding dedication to cancer immunotherapy through funding support of the SU2C-CRI Cancer Immunology Translational Research Dream Team. The second recipient of the award is Dr. Bahija Jallal, executive vice president of AstraZeneca and head of MedImmune, the global biologics research and development arm of AstraZeneca. Dr. Jallal is being honored for her work as part of the groundbreaking collaboration between MedImmune, CRI and the Ludwig Institute for Cancer Research to bring three promising immunotherapies into clinical trials.

"I'm honored to receive this award, but more importantly, I'm excited to partner with organizations like the CRI and the Ludwig Institute for Cancer Research to explore the potential of immune mediated therapies and the promise they have to become the cornerstone of future cancer treatments and help millions of patients who desperately need new treatment options," said Dr. Jallal.

In addition to the Grace Award, at the dinner CRI will bestow the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology and the Frederick W. Alt Award for New Discoveries in Immunology, which are presented annually to scientists whose outstanding contributions to cancer immunology have made a tremendous impact on the lives of cancer patients.

Nightline anchor and ABC News reporter Bill Weir will emcee the event. Folk, soul, blues and pop music duo JohnnySwim will provide musical entertainment.

Event Contact
Lynne Harmer, Director of Special Events or (212) 688-7515, ext. 226

About the Cancer Research Institute

The Cancer Research Institute (CRI), established in 1953, is the world's only nonprofit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and eventually cure all cancers. Guided by a world-renowned Scientific Advisory Council that includes three Nobel laureates and 30 members of the National Academy of Sciences, CRI has invested $240 million in support of research conducted by immunologists and tumor immunologists at the world's leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to

About the Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

This award, established in 1995, recognizes the contributions of dedicated laypersons whose leadership has had a significant impact on cancer research. The award is named in memory of the late Oliver R. Grace, founding chairman of the Cancer Research Institute, whose vision, wisdom and generosity benefited the Institute for nearly 40 years.

Former Grace Award winners include: Mark P. Frissora, Hertz Corporation chairman and CEO (2012); Mitchell H. Gold, M.D., Dendreon Corporation (2011); American fashion designer Michael Kors (2010); Andrew Witty, CEO of GlaxoSmithKline (2010); Fred Hassan, chairman and CEO of Schering-Plough Corporation (2009); Wade F.B. Thompson, chairman, CEO and co-founder of Thor Industries (2007); Julian H. Robertson Jr., chairman, Tiger Management LLC (2006); Katie Couric, anchor of CBS Evening News (2002); and Andrea Jung, Avon Products, Inc. CEO (2001). To view a complete list of Grace Award recipients, go to

SOURCE Cancer Research Institute
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
3. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
7. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
8. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
9. National Jewish Health, the Nations Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
10. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
11. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
Post Your Comments:
(Date:11/27/2015)... UTRECHT , Niederlande, November 27, 2015 /PRNewswire/ ... mit fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... fotodynamischer Bremachlorin-Therapie bei fortgeschrittenem Krebs.   ... berichtet. --> Clinical Cancer Research ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... -- Research and Markets ( ) has announced the ... to 2019 - Rise in Cardiac Disorders and Growing Awareness ... their offering. Boston scientific ... scientific and others. --> The market is ... Boston scientific and others. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent ... sharing, the 2016 Building Better Radiology Marketing Programs meeting will showcase ... Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop improving ... only fulfilling the needs of advisers and clients but going above and beyond ... top-tier customer service. However, there's always room for improvement, which is why the ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
Breaking Medicine News(10 mins):